SGHT
NASDAQ HealthcareSight Sciences, Inc. - Common Stock
Medical Devices
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and OMNI EDGE, an implant-free and minimally invasive glaucoma surgery technology. The company also provides SION, a bladeless and manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork; and TearCare system, a proprietary, interventional, dry eye device designed to melt and facilitate the comprehensive removal of meibomian gland obstructions and restore gland functionality and healthy oil production for adult patients with evaporative dry eye disease due to meibomian gland disease when used in conjunction with manual expression of the meibomian glands for ophthalmologists and optometrists. It serves hospitals, medical centers, and eyecare professionals through sales representatives and distributors. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
�� 市场数据
| 价格 | $5.20 |
|---|---|
| 成交量 | 124,552 |
| 市值 | 282.93M |
| 贝塔系数 | 2.380 |
| RSI(14日) | 42.4 |
| 200日均线 | $5.44 |
| 50日均线 | $5.06 |
| 52周最高 | $9.24 |
| 52周最低 | $3.11 |
| Forward P/E | -7.88 |
| Price / Book | 5.21 |
🎯 投资策略评分
SGHT 在各投资策略中的评分。分数越高,越符合该策略目标。
🔍 策略解读
最佳匹配: 🚀 Moon Shot (95/100) — 此策略 高增长潜力(高贝塔 + 超卖).
评分最低的策略: 💰 Dividend Daddy (3/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 SGHT in your text
粘贴任何文章、记录或帖子 — 工具将提取 SGHT 以及每一个其他隐藏的股票代码。
免责声明:本数据仅供教育和娱乐用途,不构成金融建议。市场数据可能存在延迟。在做出投资决策之前,请始终进行自己的研究。
数据最后更新: 2026-07-16.